A prospective, multicenter, non-interventional study of ibrutinib in patients with chronic lymphocytic leukemia from the german reality study
Latest Information Update: 13 Aug 2022
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 13 Aug 2022 New trial record
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association.